Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 38INDUSTRY 4NIH 3NETWORK 2UNKNOWN 1

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Breast 4Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Neoplasms 8Carcinoma, Non-Small-Cell Lung 6Prostatic Neoplasms 4Breast Neoplasms 4Neoplasm Metastasis 3Head and Neck Neoplasms 3Melanoma 2Glioblastoma 2Brain Neoplasms 2Advanced Solid Tumor 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ulnar Neuropathies 1Triple Negative Breast Neoplasms 1Solid Tumor, Adult 1Prostatic Hyperplasia 1Peripheral Lung Tumor 1Pain 1Non-Muscle Invasive Bladder Neoplasms 1Non Squamous Lung Cancer 1Neuroma 1Multiple Myeloma 1Mucositis 1Lymphoma, Follicular 1Lung Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leiomyoma 1Keratosis, Actinic 1Hyperthermia 1Glioma 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61pembrolizumab 60ribociclib 59Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × Therapeutics × Clear all
NCT00828854 2022-06-30

Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing

Syndax Pharmaceuticals

Phase 2 Completed
27 enrolled 13 charts
Breast

Breast Neoplasms

NCT01357863 2018-09-14

(TYCO1)

GlaxoSmithKline

Terminated
3 enrolled
Breast

Breast Neoplasms, Neoplasms

NCT01160094 2016-03-28

TYCO

Novartis

Completed
288 enrolled
Breast

Breast Neoplasms, Neoplasms

NCT00827177 2014-01-24

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Completed
87 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡